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BACKGROUND
Thyroid-associated ophthalmopathy, a condition commonly associated with Graves’ 
disease, remains inadequately treated. Current medical therapies, which primarily 
consist of glucocorticoids, have limited efficacy and present safety concerns. Inhi-
bition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic 
strategy to attenuate the underlying autoimmune pathogenesis of ophthalmopathy.
METHODS
We conducted a multicenter, double-masked, randomized, placebo-controlled trial 
to determine the efficacy and safety of teprotumumab, a human monoclonal anti-
body inhibitor of IGF-IR, in patients with active, moderate-to-severe ophthalmopa-
thy. A total of 88 patients were randomly assigned to receive placebo or active drug 
administered intravenously once every 3 weeks for a total of eight infusions. The 
primary end point was the response in the study eye. This response was defined 
as a reduction of 2 points or more in the Clinical Activity Score (scores range from 
0 to 7, with a score of ≥3 indicating active thyroid-associated ophthalmopathy) and 
a reduction of 2 mm or more in proptosis at week 24. Secondary end points, 
measured as continuous variables, included proptosis, the Clinical Activity Score, 
and results on the Graves’ ophthalmopathy–specific quality-of-life questionnaire. 
Adverse events were assessed.
RESULTS
In the intention-to-treat population, 29 of 42 patients who received teprotumumab 
(69%), as compared with 9 of 45 patients who received placebo (20%), had a re-
sponse at week 24 (P<0.001). Therapeutic effects were rapid; at week 6, a total of 
18 of 42 patients in the teprotumumab group (43%) and 2 of 45 patients in the 
placebo group (4%) had a response (P<0.001). Differences between the groups 
increased at subsequent time points. The only drug-related adverse event was hyper-
glycemia in patients with diabetes; this event was controlled by adjusting medica-
tion for diabetes.
CONCLUSIONS
In patients with active ophthalmopathy, teprotumumab was more effective than 
placebo in reducing proptosis and the Clinical Activity Score. (Funded by River 
Vision Development and others; ClinicalTrials.gov number, NCT01868997.)
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Medical therapies for moderate-to-severe thyroid-associated ophthal-mopathy (Graves’ orbitopathy) that have 
proved to be effective and safe in adequately 
powered, prospective, placebo-controlled trials 
are lacking. This unmet need is due to the in-
completely understood pathogenesis of the dis-
ease.1 Current treatments are inconsistently bene-
ficial and often associated with side effects, and 
their modification of the ultimate disease out-
come is uncertain.1-3 Previous clinical trials, which 
were rarely placebo-controlled, suggest that high-
dose glucocorticoids, alone3-5 or with radiother-
apy,6,7 can reduce inflammation-related signs and 
symptoms in patients with active ophthalmopa-
thy. However, glucocorticoids and orbital radio-
therapy minimally affect proptosis and can cause 
dose-limiting adverse reactions.5 In many patients, 
the condition does not improve, and in some pa-
tients it progresses to dysthyroid optic neuropathy.
The thyrotropin receptor is uniquely targeted 
in Graves’ disease by pathogenic autoantibodies 
known as thyroid-stimulating immunoglobulins.8 
These autoantibodies can be detected in most 
persons who have Graves’ disease with or with-
out ophthalmopathy.9 The expression of the thy-
rotropin receptor in orbital tissues10,11 and by orbit-
infiltrating fibrocytes12 suggests that it contributes 
to ophthalmopathy. However, the fact that thyroid-
stimulating immunoglobulins are not detectable 
in some persons with ophthalmopathy13 suggests 
that additional autoantigens may be involved.
Immunoglobulins that activate insulin-like 
growth factor I (IGF-I) receptor (IGF-IR) signal-
ing have been detected in patients with Graves’ 
disease,14 and IGF-I synergistically enhances the 
actions of thyrotropin.15 IGF-IR is a membrane-
spanning tyrosine kinase receptor with roles in 
development and metabolism.16 It regulates im-
mune function and thus might be targeted 
therapeutically in autoimmune diseases.17 IGF-IR 
is overexpressed by orbital fibroblasts18 and by 
T cells and B cells in persons with Graves’ dis-
ease.19,20 It forms a signaling complex with the 
thyrotropin receptor through which it is transac-
tivated.18 In vitro studies of orbital fibroblasts 
and fibrocytes show that IGF-IR–inhibitory anti-
bodies can attenuate the actions of IGF-I, thyro-
tropin, thyroid-stimulating immunoglobulins, and 
immunoglobulins isolated from patients with 
Graves’ disease.18,21 These observations prompted 
a trial of teprotumumab, a fully human IGF-IR–
inhibitory monoclonal antibody formerly known 
as R1507,22 in patients with active, moderate-to-
severe ophthalmopathy. In August 2016, after a 
review of the data from this trial, teprotumumab 
received a “breakthrough therapy” designation 
from the Food and Drug Administration.
Me thods
Trial Sites and Participants
The trial was conducted at 15 sites. Patients were 
recruited between July 2, 2013, and September 23, 
2015. Major inclusion criteria were the following: 
patients were 18 to 75 years of age, with oph-
thalmopathy that had been diagnosed no more 
than 9 months after the onset of symptoms, had 
a Clinical Activity Score of 4 or more on a 
7-point scale (with a score of ≥3 indicating active 
thyroid-associated ophthalmopathy) in the more 
severely affected (study) eye, and had not received 
surgical or medical treatment, with the excep-
tion of oral glucocorticoids (a cumulative dose of 
≤1 g of methylprednisolone or equivalent, with a 
6-week washout period).
Serum glucose levels in patients with diabetes 
were well controlled. Female patients had nega-
tive pregnancy tests and used approved contra-
ception. Patients with optic neuropathy, severe 
ocular surface damage, or an improved Clinical 
Activity Score of 2 points or more between 
screening and baseline visits were excluded.
Trial Design
The trial comprised three phases: screening (2 to 
6 weeks), intervention (24 weeks), and follow-up 
(48 weeks). A schedule of assessments is provided 
in Table S1 in the Supplementary Appendix, 
which is available, along with the trial protocol, 
with the full text of this article at NEJM.org.
Screening involved one to three visits. During 
the intervention phase, patients were assessed at 
baseline and every 3 weeks for 24 weeks; effi-
cacy was assessed at weeks 6, 12, 18, and 24. 
Data from week 24 were used to assess the pri-
mary and secondary end points. With the excep-
tion of rare instances, at every assessment, patients 
were evaluated by the same ophthalmologist, who 
was unaware of the trial-group assignments. A 
change of 2 points in the 7-component Clinical 
Activity Score was considered to be clinically 
relevant.23 Proptosis was assessed with the use of 
a Hertel exophthalmometer. Quality of life was 
evaluated with the use of the Graves’ ophthal-
mopathy–specific quality-of-life questionnaire 
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(GO-QOL),24 comprising two subscales assessed 
separately or in combination; scores on each sub-
scale as well as the score on the overall GO-QOL 
scale have a range of 0 to 100 points. A change 
of 8 points was considered to be clinically rele-
vant. Subjective diplopia was assessed by cate-
gorizing patients according to four grades. A 
change of one grade was considered to be clini-
cally relevant (see the Supplementary Appendix).
Trial Oversight
The trial was designed by the academic investi-
gators in collaboration with the manufacturer of 
teprotumumab, River Vision Development, which 
provided primary financial support for the trial. 
River Vision Development provided teprotumu-
mab free of charge and was responsible for trial 
oversight.
Institutional review and ethics committees of 
the participating centers and the investigators 
approved the research protocol. An independent 
data and safety monitoring board oversaw the 
safety aspects of the trial. Witnessed written 
informed consent was obtained from all pa-
tients. Data were obtained by the investigators 
and their staff.
The investigators vouch for the accuracy and 
completeness of the data generated at their re-
spective institutions. The investigators and River 
Vision Development vouch for the fidelity of the 
trial to the protocol.
Interventions
Teprotumumab was provided as freeze-dried pow-
der in glass vials. The placebo was 0.9% sodium 
chloride solution supplied by the research phar-
macy. Patients received eight intravenous infu-
sions, one every 3 weeks starting with an initial 
dose of 10 mg per kilogram of body weight, 
followed by 20 mg per kilogram for the remain-
ing seven infusions.
Randomization and Masking
This randomized trial was designed to assess 
efficacy and safety. Patients were randomly as-
signed in the double-masked intervention phase 
to either of two intervention groups in a 1:1 ratio 
in blocks of two, stratified within each clinical 
center according to smoking status with the use 
of an interactive Web-response system. Study 
pharmacists who were aware of the trial-group 
assignments prepared the masked infusion. The 
on-site principal investigators could identify a 
patient’s intervention only in the case of an 
emergency.
Outcomes
Patients who had a response were defined as 
those who met the composite primary end point 
at week 24. This end point comprised a reduction 
of 2 points or more in the Clinical Activity Score 
Figure 1 (facing page). Screening, Randomization, 
 Response, and Follow-up of Trial Patients.
As shown in Panel A, patients who met the primary in-
clusion criteria for disease that was diagnosed 9 months 
or less after the onset of symptoms and who had a 
Clinical Activity Score of 4 points or more (on a scale 
from 0 to 7, with a score of ≥3 indicating active thyroid-
associated ophthalmopathy) were entered into the 
screening phase of the trial. One patient who did not 
meet the screening criteria for an “administrative reason” 
was screened after the screening period was closed.  
At the baseline visit (week 0), patients who met all in-
clusion and exclusion criteria were randomly assigned 
to receive teprotumumab or placebo in a 24-week in-
tervention phase of the trial. Patients then entered a 
1-year follow-up phase, which is ongoing. The intention-
to-treat population was defined as all patients who re-
ceived one infusion of teprotumumab or placebo and 
excluded one patient who was randomly assigned to 
teprotumumab but withdrew consent before the drug 
was administered. One patient discontinued the inter-
vention during the intervention phase but returned for 
the week 24 assessment. As shown in Panels B through 
D, the primary end point was a logistic regression of 
response status according to trial-drug group at week 
24. A response was defined as a reduction of 2 mm or 
more in proptosis and a reduction of 2 points or more 
in the Clinical Activity Score in the study eye, without 
an equivalent increase in proptosis or in the Clinical 
Activity Score in the nonstudy eye. The Clinical Activity 
Score, which comprises seven components, ranges from 
0 to 7, and a change of 2 points is considered to be 
clinically relevant.23 As shown in Panel B, in the analysis 
of the time to first response, data are expressed as means 
±SE. As shown in Panel C, in the analysis of the time 
course in patients who met the response criteria, P values 
were calculated with the use of a logistic-regression 
model. As shown in Panel D, in the grading of a re-
sponse at week 24, P<0.001 was calculated with the 
use of a logistic-regression model. A high response in-
dicates that proptosis was reduced by 3 mm or more 
and the Clinical Activity Score was reduced by 3 points 
or more. A response indicates a reduction of 2 mm or 
more but less than 3 mm in proptosis and 2 points  
or more but less than 3 points in the Clinical Activity 
Score. A low response indicates reductions of 1 mm  
or more but less than 2 mm in proptosis and 1 point or 
more but less than 2 points in the Clinical Activity Score. 
No response indicates that the patient did not meet 
any response criteria or had missing evaluations at 
week 24.
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and a reduction of 2 mm or more in proptosis in 
the study eye in the absence of a corresponding 
amount of worsening in the nonstudy eye.
Secondary end points were proptosis and the 
Clinical Activity Score (both measured as con-
tinuous variables over time) and assessment of 
the patient’s quality of life with the use of the 
GO-QOL instrument (which includes two sub-
scales that measure limitations in visual func-
tioning and psychosocial functioning as a conse-
quence of changed physical appearance). Patients 
were also categorized according to their level of 
response. Safety was assessed according to the 
incidence of adverse events, serious adverse 
events, and withdrawals due to adverse events.
Statistical Analysis
We estimated that a sample of 84 patients would 
provide the trial with a power of 80% or more to 
detect a between-group difference if 42 patients 
per trial group had data that could be evaluated. 
On the basis of published trial results, it was 
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expected that 30% of the patients in the placebo 
group and 60% of the patients in the teprotu-
mumab group would have a response. All statis-
tical tests were two-sided and performed at the 
5% significance level. No interim data analysis 
was performed. Analyses were performed with 
the use of SAS software, version 9.1 (SAS Insti-
tute), after database lock.
The intention-to-treat population, which in-
cluded all randomly assigned patients who re-
ceived at least one infusion, was used to analyze 
the primary and secondary efficacy outcomes. 
The safety population, which included all patients 
who received teprotumumab or placebo, was used 
for all safety analyses.
In the primary analysis, we used a logistic-
regression model with the intervention group as 
the model effect and smoking as a covariate. 
Patients who did not have week 24 data for any 
reason were considered to have treatment failure. 
Results of a stratified Cochran–Mantel–Haenszel 
chi-square test, with smoking status as the strat-
ification factor, enabled confirmation of the 
logistic analysis results (see Table S5 in the Sup-
plementary Appendix).
For assessment of the secondary end points 
(proptosis, Clinical Activity Score, and GO-QOL 
scores), a mixed model of repeated measurements 
was fit to the individual change from baseline 
with the use of the PROC MIXED procedure in 
SAS software. Each baseline score (including 
smoking status, intervention group, time, time 
according to intervention, and time according to 
baseline interaction) was incorporated into the 
analysis. Responses in the nonstudy eye were 
assessed with the use of identical analyses.
R esult s
Patients
A total of 88 eligible patients underwent ran-
domization. Of these patients, the intention-to-
treat population of 87 patients (45 in the placebo 
group and 42 in the teprotumumab group) had 
more than one infusion. A total of 39 patients in 
the placebo group (87%) and 37 patients in the 
teprotumumab group (88%) completed the inter-
vention (Fig. 1A).
Baseline characteristics of the patients are 
shown in Table 1, and in Table S2 in the Supple-
mentary Appendix. A breakdown of randomiza-
tion according to clinical center is provided in 
Table S3 in the Supplementary Appendix. All 
patients met criteria for euthyroid status (within 
±50% of the reference range) at trial entry; 25 of 
87 patients (29%) had minor adjustments in the 
dose of levothyroxine or an antithyroid drug.
Although patients were stratified according to 
smoking status, there was an imbalance between 
the two groups with respect to this variable 
(Table 1). The P values associated with the ad-
justed odds ratios presented in the next section, 
as well as the P values for the reduced proptosis 
and the reduction in the Clinical Activity Score 
(both measured as continuous variables) and for 
the GO-QOL score, were calculated with the use 
of analytic methods that adjusted for a potential 
imbalance in smoking status by including smok-
ing as a covariate.
Primary and Secondary End Points
Proptosis, the Clinical Activity Score, and the 
GO-QOL score were nearly identical at baseline 
in the two groups (Table 2). At baseline, there was 
an imbalance between the groups with respect to 
diplopia, with a higher occurrence in the tepro-
tumumab group.
In the primary outcome measure in the inten-
tion-to-treat population, 9 of 45 patients who re-
ceived placebo (20%) and 29 of 42 patients who 
received teprotumumab (69%) had a response at 
week 24 (adjusted odds ratio, 8.86; P<0.001). 
Similarly, in the per-protocol population, 8 of 36 
patients who received placebo (22%) and 26 of 
33 patients who received teprotumumab (79%) 
had a response at week 24 (adjusted odds ratio, 
12.73; P<0.001). The time to the first response 
was markedly shorter in the teprotumumab group 
than in the placebo group (Fig. 1B). The onset of 
the response was rapid. The proportion of pa-
tients who had a response was greater in the 
teprotumumab group than in the placebo group 
at weeks 6, 12, and 18 (P<0.001 for all compari-
sons) (Fig. 1C). In a separate analysis that graded 
the level of response, more patients in the tepro-
tumumab group than in the placebo group had 
reductions of 3 points or more in the Clinical 
Activity Score and reductions of 3 mm or more 
in proptosis (P<0.001 for the comparisons at 
every level of response) (Fig. 1D).
At weeks 6, 12, 18, and 24, the reduction in 
proptosis from baseline, measured as a continu-
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Characteristic
Teprotumumab 
(N = 43)
Placebo 
(N = 44)
Demographic and clinical characteristics
Age — yr 51.6±10.6 54.2±13.0
Female sex — no. of patients (%) 28 (65) 36 (82)
Time since initiation of treatment for thyroid disease — mo†
Median 8 15
Range 1–134 3–189
Current treatment for thyroid disease — no. of patients (%)
Antithyroid drug‡ 15 (35) 20 (45)
Levothyroxine 26 (60) 23 (52)
Thyroid extract 1 (2) 3 (7)
Adjustment of medication at trial entry — no. of patients (%)
Levothyroxine 8 (19) 5 (11)
Antithyroid drug 5 (12) 7 (16)
Duration of eye symptoms or signs — mo 4.7±2.1 5.2±2.3
Duration of Graves’ disease — mo
Median 10.7 10.8
Range 1.2–228.0 1.2–299.0
Smoking status — no. of patients (%)§
Nonsmoker 32 (74) 26 (59)
Smoker 11 (26) 18 (41)
Biochemical characteristics
Thyrotropin-binding inhibitory immunoglobulins — % 51.6±26.9 48.7±25.4
Thyroid-stimulating immunoglobulins — % 422.9±118.1 435.1±105.2
Mean thyroid hormone levels — pmol/liter¶
Free triiodothyronine 4.8±1.4 4.9±1.7
Free thyroxine 16.3±4.8 16.3±3.6
Levels of free triiodothyronine and free thyroxine — no. of patients (%)
Euthyroid at baseline and through intervention phase 20 (46) 13 (30)
Values occasionally outside normal range during intervention phase 18 (42) 25 (57)
Sustained out-of-range values during intervention phase 5 (12) 6 (14)
*  Plus–minus values are means ±SD. Additional patient characteristics are provided in Table S2 in the Supplementary Appendix. Patients 
were recruited in the following countries: Germany (19 patients), Italy (6), the United Kingdom (10), and the United States (53). A break-
down of randomization according to clinical center is provided in Table S3 in the Supplementary Appendix. Unless otherwise stated, base-
line characteristics shown are from the safety population (44 patients in the placebo group and 43 patients in the teprotumumab group), 
which differs from the intention-to-treat population (45 patients in the placebo group and 42 patients in the teprotumumab group), since  
1 patient in the placebo group received teprotumumab in error.
†  Data shown are for 10 patients in the placebo group and 10 patients in the teprotumumab group.
‡  The antithyroid drugs were carbimazole, methimazole, and propylthiouracil.
§  Data for smoking status were based on patients who were current smokers at the time of the screening visit. Patients were stratified at ran-
domization according to smoking status to balance the trial groups with respect to this known risk factor for thyroid-associated ophthal-
mopathy. However, there were imbalances in randomization blocks and discrepancies between patients who were randomly assigned to an 
intervention as nonsmokers at week 0 and those recorded as being smokers in their case-report forms. Data from the case-report forms 
were considered to be more accurate and were used to define smoking status at baseline.
¶  The normal ranges of free triiodothyronine are 2.3 to 4.2 pg per milliliter (3.5 to 6.5 pmol per liter), and of free thyroxine, 0.9 to 1.8 ng per 
deciliter (11.6 to 23.2 pmol per liter).
Table 1. Baseline Characteristics of the Patients.*
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ous variable, was significantly greater in patients 
who received teprotumumab than in those who 
received placebo (P<0.001 for all comparisons) 
(Fig. 2A). At week 24, a total of 17 of 42 patients 
(40%) who received teprotumumab had a reduc-
tion of 4 mm or more in proptosis, as compared 
with 0% of patients who received placebo.
At weeks 6, 12, 18, and 24, the reduction in 
the Clinical Activity Score in the teprotumumab 
group was also significantly greater than that in 
the placebo group (P<0.001 for all comparisons) 
(Fig. 2B), although this score also decreased 
markedly and progressively in the placebo group. 
The baseline Clinical Activity Score in the tepro-
tumumab group was 5.1 points, and the mean 
reduction at week 24 was 4 points; this indicates 
that some patients had a near-maximal thera-
peutic effect. This finding was confirmed by a 
post hoc categorical analysis involving patients 
who had a Clinical Activity Score of 0 points or 
1 point; this analysis showed that 69% of the 
patients who received teprotumumab had a 
Clinical Activity Score of 0 or 1 at week 24, as 
compared with 21% of the patients who received 
placebo (adjusted odds ratio, 8.97; P<0.001) 
(Fig. 2C). A post hoc analysis showed that the 
Figure 2. Secondary Efficacy End Points.
Panel A shows the change in proptosis from baseline. Panel B shows the change in the Clinical Activity Score from baseline. Panel C 
shows the results of the post hoc analysis of the percentage of patients with a Clinical Activity Score of 0 or 1 through week 24. Panel D 
shows the change in the visual-functioning subscale of the Graves’ ophthalmopathy–specific quality-of-life scale (GO-QOL) from baseline. 
Scores on the visual-functioning subscale range from 0 to 100, and a change of 8 points is considered to be clinically relevant. Panel E 
shows the change in the GO-QOL appearance subscale from baseline. Scores on the appearance subscale range from 0 to 100, and a 
change of 8 points is considered to be clinically relevant. In Panels A, B, D, and E, means ±SE are shown, and P values were calculated 
with the use of a mixed model of repeated-measurements analysis involving the intention-to-treat population (45 patients in the placebo 
group and 42 patients in the teprotumumab group). Panel F shows the response with respect to subjective diplopia. In this assessment, 
patients are categorized according to four grades, and a change of one grade or more is considered to be clinically relevant. P values shown 
in Panels C and F were calculated with the use of the chi-square test comparing data from patients who had a response with data from 
those who did not.
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reductions in the Clinical Activity Score in the 
teprotumumab group were broad-based (i.e., 
they were not driven by large decreases in sub-
sets of the Clinical Activity Score components). 
Reductions in the Clinical Activity Score seen in 
the placebo group were similarly broad-based.
The GO-QOL visual-functioning score increased 
significantly in the teprotumumab group at all 
time points (Fig. 2D). This increase ranged from 
12.8 to 15.6 points greater than the increase in 
the placebo group. On the GO-QOL appearance 
subscale, a consistent trend toward improvement 
emerged but did not achieve significance (Fig. 2E). 
When the two scales were combined, signifi-
cance was seen at weeks 6, 12, and 24 (P = 0.003, 
P = 0.007, and P = 0.012, respectively) (Table 2). 
Response rates with respect to subjective diplopia 
were also significantly higher in the teprotumu-
mab group than in the placebo group (Fig. 2F).
Efficacy was also assessed at week 28 (7 weeks 
after the final dose was administered), and this 
assessment showed no evidence of diminution 
(i.e., no “rebound” phenomenon). Indeed, the 
numbers of patients with a response increased 
and proptosis and the Clinical Activity Score 
were further reduced at week 28 as compared with 
week 24. The efficacy of teprotumumab in the 
nonstudy eye was also similar to the efficacy in 
the study eye with respect to response rates, 
proptosis, and the Clinical Activity Score. Serum 
assays showed no drug-induced changes in inter-
leukin-6, interleukin-16, and RANTES (regulated 
on activation, normal T-cell expressed and secret-
ed) levels. During the intervention phase, levels of 
thyroid-stimulating immunoglobulins and thyro-
tropin-binding inhibitory immunoglobulins de-
creased progressively (by 15 to 30%) in the two 
groups.
Safety
Adverse events that emerged during the inter-
vention phase, that occurred in more than 5% of 
patients in the teprotumumab group, and that 
were greater in number in the teprotumumab 
group than in the placebo group are listed in 
Table 3. The majority of adverse events were mild, 
involved no treatment, and resolved while the 
patients continued to receive the intervention. 
Hyperglycemia, the only adverse event clearly 
identified by the investigators as being related to 
teprotumumab, was monitored by assessing blood 
glucose and glycated hemoglobin levels. Hyper-
glycemia in patients who did not have diabetes 
was uniformly grade 1, was intermittent, and 
occurred at similar rates in the two groups. 
Grade 2 or 3 hyperglycemia occurred in some 
patients with diabetes who received teprotumu-
mab, and it was well controlled after adjustment 
of the medication for diabetes. Glycemic control, 
assessed according to the glycated hemoglobin 
level, was similar to that at baseline levels after 
the intervention phase in all patients who received 
teprotumumab (Table S4 in the Supplementary 
Appendix).
No deaths occurred during the trial. A total 
of 6 patients in each group discontinued the 
intervention. Serious adverse events occurred in 
5 of 43 patients in the teprotumumab group 
(12%) and in 1 of 45 patients in the placebo 
group (2%) (Table 3). Two serious adverse events 
(diarrhea and mental confusion) in patients who 
received teprotumumab were categorized by the 
investigators as “possibly related” to the drug. 
Other serious adverse events were categorized as 
“unrelated.” Although designated as having a 
nonresponse treatment failure in the analyses, 
these 5 patients all met response criteria at their 
early withdrawal visit. Antidrug antibodies were 
detected in 1 patient in the teprotumumab group 
at baseline and in 1 patient during the interven-
tion phase (week 3). Both patients tested nega-
tive on subsequent visits (at weeks 9 and 24), and 
neither patient had neutralizing antibodies. Four 
patients in the placebo group tested positive for 
antidrug antibodies at baseline; all were graded 
as having low-level antibody responses.
Discussion
Patients who received teprotumumab had reduc-
tions in proptosis, the Clinical Activity Score, the 
GO-QOL (both the visual-functioning subscale 
and combined scales), and subjective diplopia 
that were clinically meaningful and significant 
(P≤0.001 for all comparisons with placebo).25 The 
reductions observed across all components of 
the Clinical Activity Score suggest a therapeutic 
mechanism upstream from the inflammation in 
orbital tissues. The marked reduction in propto-
sis is similar to that reported after decompression 
surgery.26,27 Moreover, orbital surgery can provoke 
reactivation of ophthalmopathy and can cause or 
exacerbate strabismus.26,28 Taken together, these 
findings suggest that inhibition of IGF-IR in pa-
tients with ophthalmopathy may result in a disease-
modifying reduction in the volume of orbital fat, 
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Variable
Teprotumumab 
(N = 43)* 
Placebo 
(N = 44)*
Summary Details of Adverse Events  
in Teprotumumab Group
number of patients (percent)
Adverse event during intervention†
Nausea 8 (19) 4 (9) Generally mild and reported after first and second 
 infusions
Muscle spasms 8 (19) 2 (5) Intermittent, 2 of 8 patients had muscle spasms for  
>1 wk and received muscle relaxants
Diarrhea 6 (14) 2 (5) Treatment occurred in 2 of 6 patients, 1 case desig-
nated as a serious adverse event (see below)
Hyperglycemia 5 (12) 2 (5) Mechanism-based adverse event
Alopecia 3 (7) 2 (5) All mild and no treatment necessary
Dry skin 3 (7) 0 All mild, 1 patient used topical dry-skin cream
Dysgeusia 3 (7) 0 In 2 of 3 patients, a transient “metallic” taste reported 
on days 1–2
Headache 3 (7) 2 (5) Generally mild, 1 patient took paracetamol
Paresthesia 3 (7) 0 “Tingling” reported in nose, feet, or chest; variable  
onset and in 2 of 3 patients occurred on 1 day
Hearing impairment 3 (7) 0 Disparate symptoms, onset, and duration (i.e., one 
case of unilateral hearing impairment with onset  
16 wk after end of therapy,‡ one case of mild bi-
lateral hearing impairment that resolved, and  
one case of tinnitus in a patient with a history  
of tinnitus)
Weight loss 3 (7) 0 Variable timing; decreases ranged from 5–9 lb (11–20 kg)
Any adverse event during intervention 32 (74) 32 (73)
Serious adverse event§
Optic neuropathy¶ 0 1 (2)
Diarrhea 1 (2) 0 Severe diarrhea in 1 patient with a 6-mo history of ulcer-
ative colitis
Inflammatory bowel disease 1 (2) 0 In 1 patient with recent diagnosis of ileitis and colitis, 
inflammatory bowel disease diagnosed and treated 
while patient received trial drug
Escherichia sepsis‖ 1 (2) 0 Escherichia coli infection of unknown origin treated with 
intravenous antibiotics
Hashimoto’s encephalopathy 1 (2) 0 Provisional diagnosis after episodic mental confusion 
with no other neurologic symptoms
Urinary retention 1 (2) 0 Diagnosed after patient had an inguinal herniorrhaphy
Any serious adverse event 5 (12) 1 (2)
*  One patient in the placebo group received a single dose of teprotumumab in error at week 15. That patient is included here in the teprotumu-
mab group.
†  Adverse events of any cause were defined as those that occurred between the administration of the first dose and 30 days after the adminis-
tration of the final dose. Listed adverse events that emerged during the intervention phase are those that occurred in more than 5% of pa-
tients in the teprotumumab group and that occurred in greater numbers in the teprotumumab group than in the placebo group. Patients 
may have had more than one adverse event.
‡  This case is included because the patient had unrelated, transient eustachian-tube dysfunction while receiving teprotumumab.
§  Listed are all serious adverse events reported in the trial, including any adverse event involving hospitalization. In the teprotumumab group, 
four patients discontinued the intervention because of the following serious adverse events: diarrhea that occurred after six infusions, inflam-
matory bowel disease after seven, Escherichia coli sepsis after three, and Hashimoto’s encephalopathy after six.
¶  A total of three patients in the placebo group withdrew from the trial because of worsening eye symptoms or a lack of response. One case 
of dysthyroid optic neuropathy designated by an investigator as a serious adverse event occurred 3 days after the week 24 evaluation.
‖  This patient was the only one whose intervention was unmasked during the course of the trial.
Table 3. Adverse Events and Serious Adverse Events.
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muscle, or both. Data from studies to determine 
the mechanism underlying the drug action are 
lacking.
The rationale for examining the clinical bene-
fit of inhibiting the IGF-IR pathway in patients 
with ophthalmopathy derives from previous stud-
ies conducted in vitro. These studies showed the 
presence of autoantibodies recognizing IGF-IR 
and activating IGF-IR signaling in patients with 
Graves’ disease 14,18,29-31 and widespread IGF-IR 
overexpression in patients with Graves’ disease.14,18-20 
They also showed that thyrotropin receptor and 
IGF-IR function interdependently.18 The presence 
of specific anti–IGF-IR antibodies in patients 
with Graves’ disease remains controversial.32 
Some studies have shown their detection,14,29-31 
whereas others have not.33,34 Given the evidence 
that actions of thyrotropin and thyroid-stimulat-
ing immunoglobulins are in part dependent on 
IGF-IR activity,18,21 the clinical benefits reported 
here may result from attenuation of pathogenic 
signaling mediated through both IGF-IR and the 
thyrotropin receptor.
The encouraging safety profile of teprotumu-
mab in patients with ophthalmopathy is consis-
tent with that in previous oncology studies35,36 
and studies of other anti–IGF-IR antibodies.37 
Teprotumumab shows no detectable affinity for 
the insulin receptor; thus, the hyperglycemia that 
was observed in some patients with diabetes 
probably resulted from IGF-IR inhibition. There 
was no evidence of residual worsening of glyce-
mic control after the course of therapy. These 
findings indicate that patients with diabetes 
who receive teprotumumab will probably need 
glucose monitoring and potential adjustment of 
medication. Teprotumumab could also be asso-
ciated with muscle spasms and diarrhea, particu-
larly in patients with gastrointestinal disease; 
however, no mechanistic link has been estab-
lished. Involvement of teprotumumab in the se-
rious adverse events of Escherichia coli infection, 
mental confusion, and urinary retention (after 
herniorrhaphy) appears to be unlikely. Thrombo-
cytopenia, anemia, and fatigue that have been 
reported in previous cancer studies22,37 were not 
observed in patients with ophthalmopathy.
As of this writing, the most informative trial 
of glucocorticoids in ophthalmopathy compared 
three doses of intravenous methylprednisolone, 
and the highest cumulative dose (7.47 g) pro-
duced mean reductions of 2.7 points from base-
line in the Clinical Activity Score and 0.6 mm in 
proptosis.3 In a recent trial, rituximab did not 
result in greater reductions from baseline in the 
Clinical Activity Score or proptosis than place-
bo,38 whereas in a second trial, rituximab, as 
compared with intravenous methylprednisolone, 
was shown to reduce the Clinical Activity Score 
from baseline with no clinically meaningful ef-
fect on proptosis.39 Our trial, which showed ap-
preciable responses across multiple end points 
in the placebo group, emphasizes the importance 
of conducting double-masked, placebo-controlled 
trials in ophthalmopathy.
Our trial has limitations. We enrolled only 
patients with active disease of recent onset, with 
a Clinical Activity Score of 4 or more. Thus, the 
potential of teprotumumab in benefiting pa-
tients with milder, less active, or stable disease 
was not assessed. Longer-term observation in 
the ongoing 1-year follow-up trial phase is neces-
sary for assessing the durability of the response. 
No orbital imaging was performed; thus, it re-
mains uncertain which orbital tissues were pri-
marily affected by teprotumumab therapy. Our 
findings may have implications for other auto-
immune diseases, such as rheumatoid arthritis, 
in which IGF-IR is involved and activating anti–
IGF-IR antibodies also have been detected.17,40
In conclusion, a 24-week course of teprotumu-
mab therapy provided clinical benefit in patients 
with active, moderate-to-severe thyroid-associat-
ed ophthalmopathy by reducing proptosis and 
the Clinical Activity Score and by improving the 
patients’ quality of life.
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